Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Zidesamtinib (NVL-520) is an orally active, selective, potent, and blood-brain-barrier-crossing inhibitor of ROS1 fusion and resistance mutations, inhibits ROS1 and ROS1 G2032R, and can be used in the study of non-small-cell lung cancer and solid tumors.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 196.00 | |
5 mg | In stock | $ 493.00 | |
10 mg | In stock | $ 830.00 | |
25 mg | In stock | $ 1,480.00 | |
50 mg | In stock | $ 1,960.00 | |
100 mg | In stock | $ 2,690.00 |
Description | Zidesamtinib (NVL-520) is an orally active, selective, potent, and blood-brain-barrier-crossing inhibitor of ROS1 fusion and resistance mutations, inhibits ROS1 and ROS1 G2032R, and can be used in the study of non-small-cell lung cancer and solid tumors. |
In vivo | Female athymic Nude-Foxn1nu mice were subcutaneously implanted with tumor fragments from the CTG-0848 model. Zidesamtinib (0.04, 0.2, 1, 5, 15 mg/kg; oral gavage twice daily for 21 days) inhibited tumor volumes[1]. |
Synonyms | NVL-520 |
Molecular Weight | 419.455 |
Formula | C22H22FN7O |
CAS No. | 2739829-00-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (71.52 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Zidesamtinib 2739829-00-4 Tyrosine Kinase/Adaptors ROS Kinase NVL-520 NVL520 NVL 520 inhibitor inhibit